NEW YORK (GenomeWeb) – Ares Genetics, a two-year old subsidiary of Curetis, is progressing in its plans to develop antibiotic resistance testing. The firm recently won funding to set up a research project and new lab space from which it will offer next-generation sequencing-based diagnostic services and products, and it has also begun a collaboration with a German pharmaceutical company to use its antibiotic resistance databases for drug development.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.